Skip to content Skip to footer

PT 141: Mechanism, Research Applications and Handling Requirements

PT 141, also written PT-141 and known as bremelanotide, is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH). It has a molecular weight of about 1,025 Da and acts as an agonist at several melanocortin receptors, including MC3R and MC4R, which are Gs-coupled G protein-coupled receptors (GPCRs). In the laboratory it is studied as a tool for melanocortin receptor pharmacology, for structure-activity work on cyclic lactam peptides, and in animal behavioural neuroscience carried out under appropriate licences. This article covers its structure, mechanism, published research, applications and the analytical and handling requirements that affect data quality.

What is PT 141?

PT-141 is a cyclic peptide with the structure Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. The formula is C50H68N14O10, and the average molecular weight is about 1,025.2 Da. The ring is formed by a lactam bond between the side-chain carboxyl group of aspartic acid and the side-chain amine of lysine. The N-terminus is acetylated, the first residue is norleucine (Nle), a non-natural isosteric replacement for methionine, and the fifth residue is D-phenylalanine. The C-terminus is a free carboxylic acid.

The design follows the logic of the α-MSH message sequence. The tetrapeptide His-Phe-Arg-Trp is the core recognised by melanocortin receptors, and substituting D-Phe for L-Phe, replacing methionine with norleucine, and constraining the structure into a ring all increase potency and resistance to enzymatic degradation. The parent compound, Melanotan II (MT-II), has the same cyclic core with a C-terminal amide. Victor Hruby, Mac Hadley and colleagues at the University of Arizona designed this family of cyclic α-melanotropins in the late 1980s. PT-141 differs from MT-II only at the C-terminus, and it was developed further by Palatin Technologies, which gave it the “PT” prefix.

The relationship between these compounds causes confusion in practice. MT-II and PT-141 differ by about 1 Da, because an acid group replaces an amide, and both can appear under informal names in supplier catalogues. A certificate of analysis should therefore give the full structure and an observed mass that is consistent with the stated form. The name “bremelanotide” is the international nonproprietary name for the same molecule, and its regulatory status in other jurisdictions is outside the scope of this laboratory-focused article.

Mechanism of action

PT-141 acts on melanocortin receptors, a family of five class A GPCRs (MC1R to MC5R) that share a set of related peptide ligands derived from proopiomelanocortin. In vitro the compound is an agonist at MC1R, MC3R, MC4R and MC5R and is inactive at MC2R, the ACTH receptor. The melanocortin-4 receptor is expressed mainly in the brain and has been studied as a regulator of energy homeostasis, and published animal work on the behavioural effects of PT-141 proposes that they depend on central MC3R and MC4R activation.

The canonical signalling route is through the stimulatory G protein Gs. Agonist binding stabilises an active receptor conformation that engages Gs, activating adenylyl cyclase and raising cyclic AMP, which in turn activates protein kinase A and the transcription factor CREB. The receptors can also signal through other routes, including arrestin recruitment and coupling to Gq/11 and Gi, so different ligands can produce different signalling profiles, a property known as biased agonism.

Structural biology has clarified the binding site. Cryo-electron microscopy structures of MC4R bound to Gs and to the peptide agonists NDP-α-MSH and setmelanotide, reported by Heyder and colleagues, show how the conserved His-Phe-Arg-Trp motif occupies the orthosteric pocket and identify a calcium ion that links the ligand to transmembrane helices 2 and 3. These structures were solved with other ligands, so the PT-141-bound conformation is inferred from them and from structure-activity data.

Two practical points follow for in-vitro design. Because the compound also activates MC1R, cells expressing that receptor, such as melanocytes, will respond, and receptor-selectivity controls are needed to attribute an effect to MC4R. Because it acts through cyclic AMP, assay conditions that affect phosphodiesterase activity or adenylyl cyclase will shift dose-response curves.

What the research shows

Four sets of published work frame the field.

The first is the design of the cyclic melanotropin scaffold. The cyclic lactam α-melanotropins, including MT-II, were designed by the Arizona group using conformational analysis and quenched dynamics simulations, and shown to be far more potent than α-MSH in classical bioassays. This work established the ring-constrained His-D-Phe-Arg-Trp core that PT-141 retains, and it is the starting point for most structure-activity studies of the family.

The second is a rat behavioural study. Pfaus and colleagues reported in PNAS in 2004 on the effects of PT-141 in ovariectomised, hormone-primed female Long-Evans rats. The animals received subcutaneous PT-141 at 50, 100 or 200 μg/kg five minutes before testing in pacing chambers. The two higher doses increased solicitation behaviours and hops and darts, while lordosis and pacing were unaffected, and the compound did not cause generalised motor activation or alter the perception of sexual reward. The authors concluded that central melanocortin systems are involved in the regulation of appetitive sexual behaviour in this model. The paper is indexed on PubMed.

The third is a structural study of the target receptor. Heyder and colleagues, in Cell Research in 2021, determined cryo-EM structures of human MC4R in complex with Gs and the agonists NDP-α-MSH and setmelanotide at resolutions of 2.9 and 2.6 Å, and combined them with mutagenesis to identify the role of transmembrane helix 3 in ligand-specific interactions and the function of calcium as a cofactor. The study did not involve PT-141 itself, but it provides the best current picture of how melanocortin peptides engage the receptor. It is available on PubMed.

The fourth is a research area, not a single paper: preclinical characterisation of PT-141 in rodents. Reviews published in the early 2000s by researchers associated with the developer describe its activity in male and female animals and its proposed central site of action. Readers should consult the original papers and note that many of them come from groups with a commercial interest in the compound.

Research applications

Melanocortin receptor pharmacology is the main use. Cell lines such as HEK293 expressing individual human receptors (MC1R, MC3R, MC4R or MC5R) are exposed to the peptide, and responses are measured by cyclic AMP accumulation, CRE-reporter gene assays or arrestin recruitment. Running the compound against the full receptor panel defines its selectivity profile, and comparing it with MT-II, NDP-α-MSH and setmelanotide shows how small structural changes affect potency and signalling bias.

Structure-activity chemistry is a second area. Because PT-141 is a compact cyclic lactam peptide, it is a useful template for studying how ring size, the D-residue and terminal modifications influence receptor selectivity, stability and conformation by NMR and molecular modelling. Neuroscience research is a third. Animal studies of melanocortin signalling, conducted by licensed investigators under the Animals (Scientific Procedures) Act 1986, use the peptide as a tool to probe central pathways, and the 2004 rat study above is an example of such work.

Analytical chemistry forms a fourth area. The pair of PT-141 and MT-II is a practical test of mass spectrometry resolution, because the two differ by about 1 Da, and the compound is used for validating HPLC methods for cyclic peptides and for detecting ring-opened and epimerised impurities. Finally, melanocyte and pigmentation research uses melanocortin agonists to study MC1R signalling, and PT-141 serves as one of several comparators in such assays.

Purity, storage and handling

Verification begins with reversed-phase HPLC, monitored at 214 nm for the peptide bond and at about 280 nm for the tryptophan and histidine-containing chromophores, with purity commonly specified at 98% or above. Mass spectrometry should confirm the intact mass, with a monoisotopic [M+H]⁺ ion expected at about m/z 1025.5. Several impurities need specific attention. The uncyclised linear precursor is about 18 Da heavier, MT-II is about 1 Da lighter, and a diastereomer carrying L-phenylalanine in place of the D-residue may co-elute with the main peak unless the gradient is optimised. Net peptide content is a separate figure, because the vial also contains counter-ions and water.

Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing PT 141 should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and researchers asking How to buy best peptides can treat those same documentation requirements as a first filter when comparing vendors.

A batch-specific certificate matters because the impurity profile of a cyclic peptide depends on how efficiently the ring closure step ran in that particular batch. The certificate should give the batch number, the HPLC conditions and chromatogram, the observed mass, the salt form, the net peptide content and the test date. The salt form is worth checking, because residual trifluoroacetate can affect cell-based cyclic AMP assays and should be matched with a vehicle control or replaced by an acetate form.

Lyophilised peptide is generally stored at -20°C, sealed and desiccated, and brought to room temperature before opening so that moisture does not condense on the powder. Short exposure to ambient temperature in transit is usually tolerated by the dry powder. Once reconstituted, the cyclic structure and the norleucine residue protect against some of the commonest degradation routes, since the ring limits exopeptidase susceptibility and norleucine cannot oxidise like methionine, but the tryptophan residue can still oxidise, and hydrolysis and adsorption to plastic can reduce the effective concentration. Stock solutions are therefore normally kept at 2-8°C for short periods and divided into single-use aliquots to avoid repeated freeze-thaw cycles, with low-binding tubes preferred for dilute working solutions. Exact stability windows depend on buffer, pH and concentration, so they should be taken from supplier data and confirmed in-house for critical assays.

Light sensitivity deserves attention because of the tryptophan, which can undergo photo-oxidation under prolonged illumination, so amber vials or dark storage are advisable for powder and solutions. Standard COSHH assessment and institutional waste procedures apply.

Frequently asked questions

What is PT-141 and is it the same as bremelanotide?

Yes. PT-141 is the research name for bremelanotide, a cyclic heptapeptide analogue of α-MSH with the structure Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH and a molecular weight of about 1,025 Da. It differs from Melanotan II only at the C-terminus, which is a free acid and not an amide.

What receptors does PT-141 act on?

In vitro it is an agonist at MC1R, MC3R, MC4R and MC5R, all Gs-coupled class A GPCRs that raise cyclic AMP. Published animal work proposes that its behavioural effects depend on central MC3R and MC4R activation, so receptor-selectivity controls are important in cell-based assays.

What is the difference between PT-141 and Melanotan II?

Both share the cyclic Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] core. Melanotan II has a C-terminal amide, while PT-141 has a free carboxylic acid, a mass difference of about 1 Da. Mass spectrometry with adequate resolution is therefore needed to distinguish them on a certificate of analysis.

How should lyophilised PT-141 be stored?

Lyophilised PT-141 is generally stored at -20°C in a sealed, desiccated container protected from light, and warmed to room temperature before opening. Reconstituted solutions are usually kept at 2-8°C for short periods as single-use aliquots, with stability limits confirmed from batch documentation.

PT 141 is supplied for in-vitro laboratory research only. It is not for human or veterinary use, and it must not be administered to people or animals.

Leave a comment

99% Purity Guarantee
Trusted By Researchers
★★★★★
Celebrating 500,000 Orders
Third party verified